Kedudukan dalam Saham
#39192
hVIVO plc (HVO) operates as a premier full-service Contract Research... hVIVO plc (HVO) operates as a premier full-service Contract Research Organisation (CRO) focused on early-phase clinical development, globally recognized as the leader in human challenge trials. The company provides a complete spectrum of clinical development services to a wide-ranging and growing client base, which includes seven of the world's ten largest biopharmaceutical companies. A key specialisation for hVIVO is orchestrating human challenge trials across numerous infectious and respiratory diseases, utilising its advanced, London-based quarantine facility, the largest of its kind globally. Additionally, the company offers extensive virology and immunology laboratory services through its hLAB division. Through its German subsidiary, CRS, hVIVO manages a 120-bed capacity across sites in Mannheim and Kiel, delivering early-phase clinical trial expertise, including first-in-human and proof-of-concept studies. Its other subsidiary, Venn Life Sciences, contributes to the biopharma sector by providing specialist early drug development consulting and biometry services. The Group collectively offers integrated drug development solutions, covering stages from preclinical research up to Phase II trials, supported by patient recruitment via FluCamp. Moreover, its five clinical sites facilitate outpatient Phase II and III trials, ensuring a streamlined and effective transition from drug discovery to late-stage development.
Perubahan (1 hari)
-1.94%
Perubahan (1 tahun)
-35.53%
Perdagangan HVIVO plc (HVO)
Bilangan saham terbitan bagi HVIVO plc (HVO)
Bilangan saham terbitan setakat August 2026: 0
Menurut laporan kewangan terkini dan harga saham HVIVO plc, bilangan saham terbitan semasa ialah 0. Pada akhir August 2026, syarikat mempunyai 0 saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk HVIVO plc (HVO) dari 2026 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun |
Saham Terbitan |
Ubah |
|
Tidak cukup data untuk tarikh yang disediakan. |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat |
Saham Terbitan |
Perbezaan |
Negara |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
0.00 |
-
|
BE
|
